Grail is exploding higher following the release of an FDA executive summary that signaled no major concerns regarding the safety and accuracy of the company's Galleri multi-cancer early detection test. The positive regulatory outlook ahead of this week's advisory committee meeting has bolstered investor confidence in the diagnostic tool's potential for premarket approval. This development serves as the primary catalyst for the stock's significant upward momentum, as the market reacts to the favorable staff review of the test's ability to detect more than 50 types of cancer.